BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HDM1002 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HDM1002\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07082114-195@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:HDM1002: Phase 3 readout est. (NCT07082114)
DESCRIPTION:HDM1002\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study to
  Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Dia
 betes Mellitus\nEstimated primary completion: 16 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hdm1002#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07082114
URL:https://assetmemo.bio/drug/hdm1002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
